{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:46Z","timestamp":1786649926271,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aim:<\/jats:title>\n                    <jats:p>\n                      There are conflicting results of studies on accuracy of positron emission tomography (PET)\/computed tomography (CT) for axillary staging. The aim of this study is to determine the factors affecting the efficacy of 18F-fluorodeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) PET\/CT in detecting axillary metastases in invasive breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Data of 232 patients with invasive breast cancer who underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT examination before surgery between January 2013 and September 2017 were reviewed retrospectively. Histopathological examination of axillary lymph nodes (ALNs) was used as a reference to assess the efficacy of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT in detecting axillary metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      While 134 (57.8%) patients had axillary metastases as detected in\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT scans, histopathologically axillary metastases were detected in 164 (70.7%) patients. The sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT in detection of axillary metastasis were 72.56%, 77.94%, 88.8%, 54%, and 74.1%, respectively. The false-negative and false-positive rates were 27.4% and 22%, respectively. In univariate analysis, patients' age, estrogen receptor positivity, higher ALN SUVmax, greater tumor size, and lymph node size determined by\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT were all significantly associated with accuracy of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT for axillary metastasis. In multivariate analysis, tumor size determined by\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT and ALN SUVmax were independent variables associated with axillary metastasis. The accuracy of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT for axillary metastasis was higher in patients with a larger tumor (\u226519.5 mm) and a higher ALN SUVmax (\u22653.2).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT should not be routinely used for axillary staging, especially in patients with small tumors. It cannot eliminiate the necessity of sentinel lymph node biopsy. When it is used, both visual information and optimal cut-off value of axillary node SUVmax should be taken into consideration.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_198_18","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T06:21:14Z","timestamp":1692598874000},"page":"63-68","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Factors Affecting the Accuracy of 18F-FDG PET\/CT in Evaluating Axillary Metastases in Invasive Breast Cancer"],"prefix":"10.4103","volume":"22","author":[{"given":"K","family":"Kutluturk","sequence":"first","affiliation":[{"name":"Department of General Surgery, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"\u015eim\u015fek","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"\u00c7omak","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"G\u00f6n\u00fclta\u015f","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"\u00dcnal","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kekilli","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251006","first-page":"262","article-title":"Prognostic factors in breast cancer","volume":"116","author":"Georgescu","year":"2012","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.20786","article-title":"Consensus Committee of the German Society of Senology. A concept for the clinical implementation of SLNB in patients with breast carcinoma with special regard to quality assurance","volume":"103","author":"Kuehn","year":"2005","journal-title":"Cancer"},{"key":"R3-20251006","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2008.01.027","article-title":"Implementation of sentinel node biopsy in breast cancer patients in the Netherlands","volume":"44","author":"Ho","year":"2008","journal-title":"Eur J Cancer"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","article-title":"Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial","volume":"252","author":"Giuliano","year":"2010","journal-title":"Ann Surg"},{"key":"R5-20251006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-004-1531-z","article-title":"FDG-PET for axillary lymph node staging in primary breast cancer","volume":"31","author":"Crippa","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20251006","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiology.203.2.9114082","article-title":"Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET","volume":"203","author":"Adler","year":"1997","journal-title":"Radiology"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/BF01249621","article-title":"Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry","volume":"23","author":"Utech","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3816\/CBC.2002.n.014","article-title":"Positron emission tomography and sentinel lymph node dissection in breast cancer","volume":"3","author":"Kelemen","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00000658-200211000-00012","article-title":"Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer","volume":"236","author":"Van der Hoeven","year":"2002","journal-title":"Ann Surg"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00006231-200603000-00005","article-title":"FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer","volume":"27","author":"Kumar","year":"2006","journal-title":"Nucl Med Commun"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdl425","article-title":"A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases","volume":"18","author":"Veronesi","year":"2007","journal-title":"Ann Oncol"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jjco\/hyp019","article-title":"Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer","volume":"39","author":"Chae","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.crad.2016.12.001","article-title":"MRI and FDG-PET\/CT based assessment of axillary lymph node metastasis in early breast cancer: A meta-analysis","volume":"72","author":"Liang","year":"2017","journal-title":"Clin Radiol"},{"key":"R14-20251006","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/archsurg.141.8.783","article-title":"Preoperative FDG-PET for axillary metastases in patients with breast cancer","volume":"141","author":"Chung","year":"2006","journal-title":"Arch Surg"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000658-200007000-00001","article-title":"Breast cancer patients treated without axillary surgery: Clinical implications and biologic analysis","volume":"232","author":"Greco","year":"2000","journal-title":"Ann Surg"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/93.8.630","article-title":"Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: Clinical evaluation and alternative management","volume":"93","author":"Greco","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"R17-20251006","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00268-008-9782-7","article-title":"Predictors of axillary lymph node metastases in breast cancer: Is there a role for minimal axillary surgery?","volume":"33","author":"Yip","year":"2009","journal-title":"World J Surg"},{"key":"R18-20251006","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1072-7515(98)00060-X","article-title":"Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center","volume":"186","author":"O'Hea","year":"1998","journal-title":"J Am Coll Surg"},{"key":"R19-20251006","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0140-6736(97)01004-0","article-title":"Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes","volume":"349","author":"Veronesi","year":"1997","journal-title":"Lancet"},{"key":"R20-20251006","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1148\/radiology.211.3.r99jn28835","article-title":"Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer","volume":"211","author":"Liberman","year":"1999","journal-title":"Radiology"},{"key":"R21-20251006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-006-9192-1","article-title":"ALMANAC Trialists Group. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer \u2013 Results of the ALMANAC validation phase","volume":"99","author":"Goyal","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"R23-20251006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/SLA.0b013e31812e6a73","article-title":"GIVOM Trialists. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: Results of the Sentinella\/GIVOM trial","volume":"247","author":"Zavagno","year":"2008","journal-title":"Ann Surg"},{"key":"R24-20251006","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial","volume":"98","author":"Mansel","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"R25-20251006","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.seminoncol.2004.03.014","article-title":"Controversial topics in breast lymphatic mapping","volume":"31","author":"Jakub","year":"2004","journal-title":"Semin Oncol"},{"key":"R26-20251006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10434-000-0021-1","article-title":"Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer","volume":"7","author":"Haigh","year":"2000","journal-title":"Ann Surg Oncol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01253091-201922010-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:05Z","timestamp":1786647605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01253091-201922010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_198_18","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2018-09-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}